Thought Leadership
FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
August 2015
Stacie Ropka, PhD and Chad Landmon
GxP Lifeline

Axinn Counsel Stacie Ropka and Partner Chad Landmon authored, "FDA Regulation of  CT/Ps – Impact of New Guidances on Manufacturers and Users," which was published in MasterControl's GxP Lifeline newsletter.

Click here to read the article. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.